biggest esports
biggest esports
None
NoneWhat Did Vexbolts Do? Users Mass Unfollowing TikToker Over 'Cringe' Content
Police deny report of kidnap at primary school( MENAFN - Dubai PR Network) Abu Dhabi, December 29, 2025 – ADNEC Group has announced its collaboration with Tawazun Council as a strategic partner to organise the largest edition of International Defence exhibition (IDEX) and Naval Defence Exhibition (NAVDEX), which will be held under the patronage of His Highness sheikh Mohammed bin Zayed Al Nahyan, President of the UAE and Supreme Commander of the Armed Forces,from 17 to 21 February 2025 at the ADNEC Centre in Abu Dhabi. This partnership underscores Tawazun Council and ADNEC Group's shared commitment to advancing the UAE's vision of becoming a leading global hub for defence, security, and advanced technology sectors. It also aims to provide a strategic platform that brings together decision-makers, experts, and industry leaders to showcase the latest innovations and technologies shaping the future of defence and security. Saeed Al Mansoori, Advisor for Defence Exhibitions at Capital Events, part of ADNEC Group, said:“We are proud of our partnership and collaboration with Tawazun Council in organising the 17th edition of IDEX and the 8th edition of NAVDEX 2025. This strategic collaboration is a testament to our collective commitment to positioning Abu Dhabi as a global capital of innovation and excellence in the defence and security sector, and a leading city in organising and hosting major specialised international events.” “We are working closely with our partners to ensure an exceptional experience for the 2025 edition, which will feature the largest participation in history. The two exhibitions will host the highest number of participants, experts, and industry leaders from around the world, coming together to develop innovative solutions that will drive the growth of the defence industry and contribute to the sustainable economic development of the UAE.” he added Mona Ahmed Al Jabber, Chief Corporate Communication Officer at Tawazun Council, emphasized that IDEX and NAVDEX are key milestones in the global defence exhibition sector. She highlighted how these events showcase significant advancements in defence and technology, while demonstrating the outstanding professionalism of the organisers and the extensive efforts dedicated to delivering an exceptional edition. These efforts draw the attention of the international community, leading companies, specialists, and decision-makers, further solidifying the UAE's role as a global hub for Meetings, Incentives, Conferences, and Exhibitions (MICE). 'We are proud to look ahead to the 2025 edition of IDEX and NAVDEX, organised by ADNEC Group in collaboration with the Ministry of Defence and Tawazun Council. This strategic partnership shows Tawazun Council's commitment to supporting defence and security exhibitions. It also reflects the strength of national partnerships and the collaboration between stakeholders to achieve the UAE's ambitious goals in this important field, fostering international cooperation, attracting high-value investments, and driving sustainable development in defence and technology.' She added The exhibitions will witness innovative programs, includingIDEX Next-Gen, a platform dedicated to global start-ups, and IDEX Think Tank, which will bring together international defence and security experts to discuss the challenges and innovations shaping the sector. Other key features include the IDEX and NAVDEX Dialogues, which will convene policymakers, thought leaders, and futurists to explore cutting-edge technologies and innovations that are defining the future of the industry. The 16th edition of IDEX and the 7th edition of NAVDEX in 2023 were highly successful, attracting 132,507 participants. The exhibitions featured 41 international pavilions and included 1,353 exhibitors from 65 countries. Tawazun Council Tawazun Council is a key government authority tasked with overseeing defence acquisitions, supporting defence R&D, promoting the growth of the industrial ecosystem, and establishing regulations, quality standards, and licensing, in close collaboration with the Ministry of Dfense and security agencies. MENAFN30122024003092003082ID1109040389 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.No. 2 Ohio State takes control in the 2nd half and runs over No. 5 Indiana 38-15
Michigan political leaders are reacting to the passing of former President Jimmy Carter. Rep. Debbie Dingell said Carter’s advocacy work involving the environment, conservation, and human rights can still be felt today. Recommended Videos “President Carter cared about humanity and believed so deeply in the importance of public service and giving back, and I hope we all continue to learn from the example he set,” she said. Dingell said her late husband, Rep. John Dingell, had a candid and honest relationship with Carter. Sen. Debbie Stabenow said America and the world lost an incredible leader. “Thank you President Carter for showing all of us what it means to lead with your values both in and out of public service. You showed us what “faith and works” really mean,” she said. Sen. Gary Peters said he and his wife are thinking of the entire Carter family. “He will be remembered as a true public servant –– from his time serving in the U.S. Navy & as President, to his decades of selfless humanitarian work,” he said. Michigan Gov. Gretchen Whitmer said Carter lived an impressive life. “In the White House, President Carter brokered peace, established the Departments of Energy and Education, advocated for solar energy, and doubled the amount of land for national parks and wildlife refuges,” she said. Whitmer also highlighted Carter’s impact after leaving office. “He dedicated decades of his life to helping those around the world who had the least. He helped build thousands of homes with Habitat for Humanity, and established the Carter Center, focused on health and human rights. And he made time to preach from his community pulpit on Sundays,” the governor said. Lt. Gov. Garlin Gilchrist said Carter a created more prosperous and peaceful world. “He understood the unique mission and meaning of public service: helping his fellow citizens live their best lives and reach their full potential. As the nation grieves his passing, let us reflect on the lessons of his life and recommit to following in his footsteps, creating a more connected and conscientious world for all of us,” he said. Michigan Attorney General Dana Nessel described Carter as a model citizen. “Among his lifetime of accomplishments, President Carter will surely be remembered for his service to our nation, his pioneering civil rights activism, his staunch commitment to environmental policy, and his extensive post-presidency humanitarian work. His legacy will honor our country for generations to come,” she said. Former Michigan Gov. Jim Blanchard worked with Carter on the financial rescue of Chrysler in 1980. President Carter signed the law granting Chrysler $1.5 billion to save the company from bankruptcy. Blanchard was serving in the House of Representatives at the time. He was the authored of the House bill. “That was a big deal. It saved the largest employer of Detroit, the largest employer of African Americans. It was a real help to the entire auto industry, which if Chrysler would have gone down would have reverberated throughout the other companies and suppliers. So, economically it was a real help to Michigan,” Blanchard said. But it wasn’t enough for Carter to win Michigan during his re-election campaign against Republican Ronald Reagan. Blanchard said initially when Chrysler ran into trouble, Carter was against any corporate bailouts or subsidies. That initial reluctance harmed his relations with Michigan, Blanchard said. “He never got the credit he should have. It’s all in the books that write about him because he did the right thing,” he said. Reagan secured 489 electoral votes to win the presidency. “When you only get one term, it’s hard to be considered a great president. I can tell you this, he was a good man. And he continued to serve the public for all these years since his defeat in 1980,” Blanchard said. Carter also didn’t win Michigan in 1976 in his race against Republican Gerald Ford. Michigan was Ford’s home state. From the Vault: Jimmy Carter, Gerald Ford campaign in Detroit in 1976USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cardiff Oncology, Inc. (NASDAQ: CRDF), Personalis, Inc. (NASDAQ: PSNL), Tempus AI, Inc. (NASDAQ: TEM), and Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 —a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025 . "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer," said Tom Heineman , M.D., Ph.D., Chief Medical Officer of Oncolytics . "Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients." Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025 , from 7:00 to 7:55 a.m. PT . Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025 , from 11:30 a.m. to 1:00 p.m. PT . Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 . CONTINUED... Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 , data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. "We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology . "Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses." Personalis, Inc. (NASDAQ: PSNL), a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. (NASDAQ: TEM), an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. "While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," said Chris Hall , CEO of Personalis . "We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity." Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. "[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC," said James Oliviero , President and CEO of Checkpoin t. "This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC." Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content: https://www.prnewswire.com/news-releases/oncology-advancements-accelerate-amid-rising-early-onset-cancer-diagnoses-302337555.html SOURCE USA News Group
- Previous:
- Next: e-sports betting
